Product Description: Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.
Applications: Cancer-Kinase/protease
Formula: C26H29N5O2
References: [1]Heinrich MC, et al.Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with STI571-resistant gastrointestinal stromal tumors. Clin Cancer Res, 2012, Jun 27./[2]Mathias TJ, et al. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Invest New Drugs. 2015 Apr;33(2):300-9./[3]Wang P, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Onco Targets Ther. 2014 Sep 26;7:1761-8.
CAS Number: 670220-88-9
Molecular Weight: 443.54
Compound Purity: 99.68
Research Area: Cancer
Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Autophagy;FLT3;PDGFR
Deutsch
English
